Patents Assigned to Novartis Vaccines and Diagnostics, Inc.
  • Patent number: 8318791
    Abstract: The present invention relates to new substituted imidazole compounds and pharmaceutically acceptable salts, esters or prodrugs thereof, compositions of the new compounds together with pharmaceutically acceptable carriers, and uses of the new compounds.
    Type: Grant
    Filed: June 5, 2009
    Date of Patent: November 27, 2012
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Weibo Wang, Paul A. Barsanti, Yia Xia, Rustum Boyce, Sabina Pecchi, Nathan Brammeier, Megan C. Phillips, Kris Mendenhall, Kelly Wayman, Liana Marie Lagniton, Ryan Constantine, Hong Yang, Elizabeth Mieuli, Savithri Ramurthy, Elisa Jazan, Anu Sharma, Rama Jain, Sharadha Subramanian, Paul A. Renhowe, Kenneth W. Bair, David Duhl, Annette Walter, Tinya Abrams, Kay Huh, Eric Martin, Mark Knapp, Vincent P. Le
  • Publication number: 20120289464
    Abstract: The present invention provides a unit dose composition comprising 0.2 ?g/kg to 48 ?g/kg of an FGF-2 of SEQ ID NO:2, or an angiogenically active fragment or mutein thereof in a pharmaceutically acceptable carrier. Also provided is a method for treating a human patient for coronary artery disease, comprising administering into one or more coronary vessels or a peripheral vein of said patient a safe and angiogenically effective dose of a recombinant FGF-2, or an angiogenically active fragment or mutein thereof. Also provided is a pharmaceutical composition comprising a therapeutically effective amount of FGF-2, alone or in combination with heparin, in a therapeutically effective carrier.
    Type: Application
    Filed: April 15, 2011
    Publication date: November 15, 2012
    Applicant: Novartis Vaccines and Diagnostics, Inc.
    Inventor: Martha Jo Whitehouse
  • Publication number: 20120288501
    Abstract: New substituted benz-azole compounds, compositions and methods of inhibition of Raf kinase activity in a human or animal subject are provided. The new compounds compositions may be used either alone or in combination with at least one additional agent for the treatment of a Raf kinase mediated disorder, such as cancer.
    Type: Application
    Filed: July 24, 2012
    Publication date: November 15, 2012
    Applicant: Novartis Vaccines and Diagnostics, Inc. formerly known as Chiron Corporation
    Inventors: Payman Amiri, Wendy Fantl, Barry Haskell Levine, Daniel J. Poon, Savithri Ramurthy, Paul A. Renhowe, Sharadha Subramanian, Leonard Sung
  • Patent number: 8309139
    Abstract: Microparticles with adsorbent surfaces, methods of making such microparticles, and uses thereof, are disclosed. The microparticles comprise a polymer, such as a poly(?-hydroxy acid), a polyhydroxy butyric acid, a polycaprolactone, a polyorthoester, a polyanhydride, and the like, and are formed using cationic, anionic, or nonionic detergents. The surface of the microparticles efficiently adsorb biologically active macromolecules, such as DNA, polypeptides, antigens, and adjuvants. Also provided are compositions of an oil droplet emulsion having a metabolizable oil and an emulsifying agent. Immunogenic compositions having an immunostimulating amount of an antigenic substance, and an immunostimulating amount of an adjuvant composition are also provided.
    Type: Grant
    Filed: April 18, 2006
    Date of Patent: November 13, 2012
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Derek O'Hagan, Gary S. Ott, John Donnelly, Jina Kazzaz, Mildred Ugozzoli, Manmohan Singh, John Barackman
  • Publication number: 20120269840
    Abstract: The present invention relates to the efficient expression of HIV polypeptides in a variety of cell types, including, but not limited to, mammalian, insect, and plant cells. Synthetic expression cassettes encoding the HIV Gag-containing polypeptides are described, as are uses of the expression cassettes in applications including DNA immunization, generation of packaging cell lines, and production of Env-, tat- or Gag-containing proteins. The invention provides methods of producing Virus-Like Particles (VLPs), as well as, uses of the VLPs including, but not limited to, vehicles for the presentation of antigens and stimulation of immune response in subjects to whom the VLPs are administered.
    Type: Application
    Filed: April 27, 2012
    Publication date: October 25, 2012
    Applicant: NOVARTIS VACCINES AND DIAGNOSTICS. INC.
    Inventors: Susan W. BARNETT, Jan ZUR MEGEDE, Indresh SRIVASTAVA, Ying LIAN, Karin HARTOG, Hong LIU, Catherine GREER, Mark SELBY, Christopher WALKER
  • Publication number: 20120269851
    Abstract: The present invention relates to polynucleotides encoding immunogenic HIV polypeptides. Uses of the polypeptides in applications including immunization, generation of packaging cell lines, and production of HIV polypeptides are also described. Polynucleotides encoding antigenic HIV polypeptides are described, as are uses of these polynucleotides and polypeptide products therefrom, including formulations of immunogenic compositions and uses thereof.
    Type: Application
    Filed: February 17, 2012
    Publication date: October 25, 2012
    Applicants: University of Stellenbosch, NOVARTIS VACCINES & DIAGNOSTICS, INC.
    Inventors: Jan zur Megede, Susan Barnett, Ying Lian, Susan Engelbrecht, Estrelita Janse van Rensburg, Thomas J. Scriba
  • Patent number: 8277810
    Abstract: Compositions and methods of therapy for treating diseases mediated by stimulation of CD40 signaling on CD40-expressing cells are provided. The methods comprise administering a therapeutically effective amount of an antagonist anti-CD40 antibody or antigen-binding fragment thereof to a patient in need thereof. The antagonist anti-CD40 antibody or antigen-binding fragment thereof is free of significant agonist activity, but exhibits antagonist activity when the antibody binds a CD40 antigen on a human CD40-expressing cell. Antagonist activity of the anti-CD40 antibody or antigen-binding fragment thereof beneficially inhibits proliferation and/or differentiation of human CD40-expressing cells, such as B cells.
    Type: Grant
    Filed: October 31, 2007
    Date of Patent: October 2, 2012
    Assignee: Novartis Vaccines & Diagnostics, Inc.
    Inventors: Li Long, Mohammad Luqman, Asha Yabannavar, Isabel Zaror, Bao-Lu Chen, Xiaofeng Lu, Sang Hoon Lee, Deborah Hurst
  • Publication number: 20120244182
    Abstract: The invention provides immunostimulatory compositions and methods of administration thereof. Also provided are methods of administering a tryptanthrin compound in an effective amount to enhance the immune response of a subject to an antigen. Also provided are methods of administering an effective amount of a tryptanthrin to stimulate the immune response in a subject for the treatment of cancer. Further provided are methods of administering a tryptanthrin compounds as an immunotherapeutic in the treatment of infectious diseases.
    Type: Application
    Filed: June 4, 2012
    Publication date: September 27, 2012
    Applicant: NOVARTIS VACCINES AND DIAGNOSTICS, INC.
    Inventor: Nicholas M. VALIANTE
  • Patent number: 8263394
    Abstract: The present invention relates to polynucleotides encoding immunogenic HIV polypeptides. Uses of the polynucleotides in applications including immunization, generation of packaging cell lines, and production of HIV polypeptides are also described. Polynucleotides encoding antigenic HIV polypeptides are described, as are uses of these polynucleotides and polypeptide products therefrom, including formulations of immunogenic compositions and uses thereof.
    Type: Grant
    Filed: January 23, 2008
    Date of Patent: September 11, 2012
    Assignee: Novartis Vaccines & Diagnostics Inc.
    Inventors: Jan zur Megede, Susan W. Barnett
  • Patent number: 8236928
    Abstract: A polynucleotide sequence as shown in SEQ ID NO:1 is associated with metastatic potential of cancer cells, especially breast cancer cells. Methods are provided for determining the risk of metastasis of a tumor, by determining whether a tissue sample from a tumor expresses a polypeptide or mRNA encoded by a polynucleotide as shown in SEQ ID NO:1. Also provided are therapeutic methods and compositions.
    Type: Grant
    Filed: June 8, 2006
    Date of Patent: August 7, 2012
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Joerg Kaufmann, Greg Harrowe, Christoph Reinhard, Sanmao Kang
  • Patent number: 8226955
    Abstract: Env-CD4 polypeptide complexes and hybrids that expose cryptic epitopes important in virus neutralization are disclosed. Method of diagnosis, treatment and prevention using the polypeptides are also provided.
    Type: Grant
    Filed: August 19, 2010
    Date of Patent: July 24, 2012
    Assignee: Novartis Vaccines & Diagnostics, Inc
    Inventors: Susan W Barnett, Indresh K Srivastava
  • Publication number: 20120183557
    Abstract: Hybrid molecules comprising CD4 minimal modules or mimetics that bind to HIV Env polypeptides in combination with one or more HIV Tat polypeptides are described. Also described are complexes of these hybrid molecules with Env as well as methods of diagnosis, treatment and prevention using the polynucleotides and polypeptides.
    Type: Application
    Filed: March 22, 2012
    Publication date: July 19, 2012
    Applicant: NOVARTIS VACCINES AND DIAGNOSTICS. INC.
    Inventors: Susan BARNETT, Rino RAPPUOLI, Victoria A. SHARMA, Indresh K. SRIVASTAVA, Jan ZUR MEGEDE
  • Patent number: 8221983
    Abstract: The present invention provides polynucleotides, as well as polypeptides encoded thereby, that are differentially expressed in cancer cells. These polynucleotides are useful in a variety of diagnostic and therapeutic methods. The present invention further provides methods of reducing growth of cancer cells. These methods are useful for treating cancer.
    Type: Grant
    Filed: March 16, 2010
    Date of Patent: July 17, 2012
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Vivien W. Chan, Jaime Escobedo, Pablo Dominguez Garcia, Rhonda Hansen, Joerg Kaufmann, Giulia C. Kennedy, George Lamson, Edward J. Moler, Filippo Randazzo, Christoph Reinhard, Julie Sudduth-Klinger
  • Publication number: 20120177657
    Abstract: Fusion proteins comprising CD4 minimal modules that bind to HIV Env polypeptides in a non-CD4 backbone are described. Also described are complexes of these fusion proteins with Env as well as methods of diagnosis, treatment and prevention using the polynucleotides and polypeptides are also provided.
    Type: Application
    Filed: March 21, 2012
    Publication date: July 12, 2012
    Applicant: NOVARTIS VACCINES AND DIAGNOSTICS, INC.
    Inventors: Vega MASIGNANI, Maria SCARSELLI, Barbara CAPECCHI, Victoria SHARMA, Susan W. BARNETT, Indresh K. SRIVASTAVA, Rino RAPPUOLI
  • Publication number: 20120171244
    Abstract: Mucosal immunization using one or more antigens following parenteral administration of the same or different antigens is described.
    Type: Application
    Filed: February 4, 2012
    Publication date: July 5, 2012
    Applicant: NOVARTIS VACCINES AND DIAGNOSTICS, INC.
    Inventor: Derek O'Hagan
  • Publication number: 20120165245
    Abstract: The present invention provides a unit dose comprising 0.2 ?g/kg to 36 ?g/kg of a recombinant FGF or an angiogenically active fragment or mutein thereof. Also provided is a pharmaceutical composition comprising an angiogenically effective dose of an FGF or an angiogenically active fragment or mutein thereof, and a pharmaceutically acceptable carrier. Also provided is a method for treating a human patient for coronary artery disease, comprising administering into at least one coronary vessel of said patient a safe and angiogenically effective dose of a recombinant FGF of any of SEQ ID NOS:1-3, 5, 8-10, or 12-14, or an angiogenically active fragment or mutein thereof.
    Type: Application
    Filed: November 17, 2010
    Publication date: June 28, 2012
    Applicant: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Martha J. Whitehouse, W. Michael Kavanaugh
  • Patent number: 8206720
    Abstract: Fusion proteins comprising CD4 minimal modules that bind to HIV Env polypeptides in a non-CD4 backbone are described. Also described are complexes of these fusion proteins with Env as well as methods of diagnosis, treatment and prevention using the polynucleotides and polypeptides are also provided.
    Type: Grant
    Filed: June 8, 2005
    Date of Patent: June 26, 2012
    Assignee: Novartis Vaccines & Diagnostics, Inc
    Inventors: Vega Masignani, Maria Scarselli, Barbara Capecchi, Victoria Sharma, Susan W. Barnett, Indresh K. Srivastava, Rino Rappuoli
  • Patent number: 8206749
    Abstract: Microparticles with adsorbent surfaces, methods of making such microparticles, and uses thereof, are disclosed. The microparticles comprise a polymer, such as a poly(?-hydroxy acid), a polyhydroxy butyric acid, a polycaprolactone, a polyorthoester, a polyanhydride, and the like, and are formed using cationic, anionic, or nonionic detergents. The surface of the microparticles efficiently adsorb biologically active macromolecules, such as DNA, polypeptides, antigens, and adjuvants. Also provided are compositions of an oil droplet emulsion having a metabolizable oil and an emulsifying agent. Immunogenic compositions having an immunostimulating amount of an antigenic substance, and an immunostimulating amount of an adjuvant composition are also provided.
    Type: Grant
    Filed: February 9, 2000
    Date of Patent: June 26, 2012
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Derek O'Hagan, Gary S. Ott, John Donnelly, Jina Kazzaz, Mildred Ugozzoli, Manmohan Singh, John Barackman
  • Patent number: 8197819
    Abstract: Provided herein are small molecule CD4 mimetics effective to bind to HIV Env proteins. A CD4 mimetic of the invention, when bound to an Env protein, is effective to induce a conformational change in the Env protein such that cyptic epitopes on the Env protein are exposed. Also provided herein are related methods of identifying and using such small molecule CD4 mimetics, for example, to elicit an immune response in a subject upon administration.
    Type: Grant
    Filed: June 8, 2005
    Date of Patent: June 12, 2012
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Indresh K. Srivastava, Victoria Sharma, Susan W. Barnett, Jeffrey Ulmer
  • Patent number: 8193185
    Abstract: The invention provides immunostimulatory compositions and methods of administration thereof. Also provided are methods of administering a tryptanthrin compound in an effective amount to enhance the immune response of a subject to an antigen. Also provided are methods of administering an effective amount of a tryptanthrin to stimulate the immune response in a subject for the treatment of cancer. Further provided are methods of administering a tryptanthrin compounds as an immunotherapeutic in the treatment of infectious diseases.
    Type: Grant
    Filed: January 21, 2004
    Date of Patent: June 5, 2012
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventor: Nicholas M. Valiante